UNSPSC 51363301: Glutethimide

This classification denotes a sedative and hypnotic with the molecular formula C13H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C8I4BVN78E, chemically known as 2,6-piperidinedione, 3-(4-aminophenyl)-3-ethyl- but generally known as glutethimide, which bears US NIH Compound Identifier 2145. European Medicines Agency schedules Glutethimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07945MIG.

UNSPSC 51363301 Glutethimide is a Commodity code that in recent state and local practice represents procurement of pharmaceutical products, though the code's nominal scope and actual solicitation activity show significant misalignment. Seminole County, Florida and the Texas Health and Human Services Commission have posted opportunities tagged to this code that involve naloxone, safe drug deactivation systems, and direct-to-manufacturer prescription programs — none of which are glutethimide specifically. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) has solicited generic multi-source pharmaceuticals and over-the-counter products through a two-year contract vehicle. State and local issuing bodies under this code include county health departments (Seminole County), state health and human services agencies (Texas HHS Commission), and cooperative purchasing organizations (MMCAP, serving Minnesota and Oregon). The work involves supply of finished pharmaceutical products, quarterly or ongoing delivery to health facilities or distribution through authorized wholesalers, compliance with FDA requirements and Drug Supply Chain Security Act standards, and maintenance of NDC (National Drug Code) information and pricing transparency.

Recent activity clusters in Florida, Texas, and the Upper Midwest (Minnesota, Oregon). Seminole County issued IFB 60459723LAS in June 2026 for naloxone and drug deactivation systems with a July 26, 2023 response deadline, procuring 1,900 units of naloxone and 800 deactivation units annually through quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas HHS Commission posted Request for Information HHS0017013 on April 3, 2026 to explore direct-to-manufacturer prescription programs and vendor capacity outside traditional pharmacy benefit manager structures, with no formal award timeline disclosed. MMCAP issued RFP S1070000015802 in January 2026 (response deadline March 26, 2026) for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with contracts effective July 1, 2026 and pricing weighted 75 percent on competitiveness. The code shows limited recent activity directly aligned to glutethimide procurement; opportunities tagged to it reflect broader pharmaceutical sourcing across health departments and cooperative purchasing structures rather than targeted procurement of a specific drug substance.